← 홈

CGT · 다발성 골수종

131개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 131개
CGTBiologicstaleUnion Hospital, Tongji Medical …Phase 1

CD19/BCMA CAR-T cell therapy (CD19/BCMA CAR-T cell therapy)

Systemic Lupus Erythematosus · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleYake Biotechnology Ltd.Phase 1

CD19/BCMA Targeted CAR T-cells and dasatinib (CD19/BCMA Targeted CAR T-cells and dasatinib)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleWest China HospitalPhase 1

CD19/BCMA in vivo CAR-T (CD19/BCMA in vivo CAR-T)

Autoimmune Diseases · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleThe First Affiliated Hospital o…Phase 1

CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T, CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells, CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing)

Refractory Idiopathic Membranous Nephropathy · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleZhejiang UniversityPhase 1

CD19/BCMA-targeted CAR-T cells (CD19/BCMA-targeted CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleShanghai Cell Therapy Group Co.…Phase 1

CD19/CD20/BCMA CAR T cells (CD19/CD20/BCMA CAR T cells)

Non-Hodgkin Lymphoma, B-cell · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleShanghai Cell Therapy Group Co.…Phase 1

CD19/CD20/BCMA CAR-T (CD19/CD20/BCMA CAR-T)

Relapsed; Refractory · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleShanghai Cell Therapy Group Co.…Phase 1

BZE2204 (CD19/CD22/BCMA CAR-T cells, CD19/CD22/BCMA CAR-T cells(BZE2204))

Idiopathic Inflammatory Myopathies(IIM); Immune Thrombocytopenia(ITP) · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Preclinical

CT0590 CAR T Cells (CT0590 CAR T Cells)

Relapsed and/or Refractory Multiple Myeloma · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleSichuan UniversityPhase 1

CXCR4 modified anti-BCMA CAR T cells (CXCR4 modified anti-BCMA CAR T cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleO&D BioTech Group CO., LimitedPhase 1

Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D (Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D)

Relapsed or Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing GoBroad HospitalPhase 1

Dual-targeting BCMA-CD19 CAR-T cell infusion (Dual-targeting BCMA-CD19 CAR-T cell infusion)

Relapsed or Refractory Multiple Myeloma (RRMM) · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleMemorial Sloan Kettering Cancer…Phase 1

EGFRt/BCMA-41BBz CAR T cell (EGFRt/BCMA-41BBz CAR T cell)

Multiple Myeloma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleUniversity of ArkansasPhase 2

ENK Cell Infusion (ENK Cell Infusion)

Asymptomatic Multiple Myeloma · Asymptomatic Multiple Myeloma

#AsymptomaticMultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Phase 1

Experimental: CAR-T cells Infusion (Experimental: CAR-T cells Infusion)

Multiple Myeloma; Primary Plasma Cell Leukemia · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleFate TherapeuticsPhase 1

Allogenic CAR NK cells with BCMA expression (FT576, FT576 (Allogenic CAR NK cells with BCMA expression))

Multiple Myeloma; Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleMedical College of WisconsinPhase 1

1 x 10^8 cells per dose (FT836 CAR T cells, FT836 CAR T cells (1 x 10^8 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleMedical College of WisconsinPhase 1

3 x 108 cells per dose (FT836 CAR T cells, FT836 CAR T cells (3 x 108 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleMedical College of WisconsinPhase 1

up to 9 x 108 cells per dose (FT836 CAR T cells, FT836 CAR T cells (up to 9 x 108 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleNanjing IASO Biotechnology Co.,…Phase 1

CT103A (Fully human BCMA chimeric antigen receptor autologous T cell injection, Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE

5 / 7 페이지

← 이전다음 →